文献速递先天性心脏病外科

Fontan术后华法林使用与血栓栓塞事件关联的倾向评分重叠加权分析

Association between warfarin use and thromboembolic events in patients post-Fontan operation: propensity-score overlap weighting analyses.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

基于日本诊断程序组合数据库2011年4月至2022年3月的回顾性队列研究,纳入2007例Fontan术后患者,其中华法林组1670例、非华法林组337例,采用倾向评分重叠加权分析。平均随访2.1年,华法林组与非华法林组血栓栓塞事件粗比例均为3.0%,出血事件分别为0.4%和0.3%。加权后两组血栓栓塞事件(亚分布风险比0.77,95%CI 0.39-1.51,P=0.45)和出血事件(亚分布风险比0.78,95%CI 0.09-7.03,P=0.83)均无显著差异。

要点

  • Fontan术后出院时使用华法林未显著降低血栓栓塞事件风险(SHR 0.77,95%CI 0.39-1.51,P=0.45)。
  • 华法林组与非华法林组出血事件风险亦无显著差异(SHR 0.78,95%CI 0.09-7.03,P=0.83)。
  • 基于大规模真实世界数据,儿童Fontan术后常规华法林预防血栓栓塞可能并非必要。

核心结论

  • Fontan术后出院时使用华法林可能无需用于儿童患者的血栓栓塞预防,基于平均术后随访2.1年的大规模真实世界数据。
  • 有必要进一步研究重新考虑Fontan术后常规使用华法林。

研究设计与样本

  • 回顾性队列研究,使用日本诊断程序组合数据库2011年4月至2022年3月数据。
  • 纳入所有接受Fontan手术的患者,排除2010年前出生、住院期间死亡或接受机械心脏置换者。
  • 共识别2007例 eligible 患者,华法林组1670例,非华法林组337例。
  • 采用倾向评分重叠加权比较出院带华法林(伴或不伴阿司匹林)与对照组(仅阿司匹林或既无阿司匹林也无华法林)。
  • 使用Cox和Fine-Gray风险模型比较血栓栓塞和出血事件。

主要发现

  • 平均随访时间2.1年。
  • 华法林组和非华法林组血栓栓塞事件粗比例均为3.0%。
  • 华法林组和非华法林组出血事件粗比例分别为0.4%和0.3%。
  • 两组血栓栓塞事件无显著差异(亚分布风险比0.77;95%CI 0.39-1.51;P=0.45)。
  • 两组出血事件无显著差异(亚分布风险比0.78;95%CI 0.09-7.03;P=0.83)。

临床怎么用

  • 对于儿童Fontan术后患者,出院时常规使用华法林预防血栓栓塞可能并非必要,需结合个体化风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The appropriate antithrombotic regimen after a Fontan operation is yet to be elucidated. Hence, this study aimed to compare the incidence of thromboembolic events in patients with and without receiving warfarin for thromboprophylaxis in a large post-Fontan population. METHODS: This retrospective cohort study used data from the Diagnosis Procedure Combination database in Japan between April 2011 and March 2022. We identified all patients who underwent a Fontan operation and excluded those who were born before 2010, died during the hospitalization or received mechanical heart replacement. Propensity score overlap weighting was performed between patients discharged with warfarin (with or without aspirin) and the control group (only aspirin or neither aspirin nor warfarin). Cox and Fine-Gray hazards models compared thromboembolic and bleeding events. RESULTS: We identified 2007 eligible patients, including 1670 warfarin users and 337 non-users. The mean follow-up duration was 2.1 years. The crude proportions of thromboembolic events were 3.0% and 3.0% and those of bleeding events were 0.4% and 0.3% in the warfarin and control groups, respectively. There was no significant difference in thromboembolic events between the groups (sub-distribution hazard ratio: 0.77; 95% confidence interval 0.39-1.51; P = 0.45) or bleeding events (sub-distribution hazard ratio: 0.78; 95% confidence interval 0.09-7.03; P = 0.83). CONCLUSIONS: Warfarin use at discharge after a Fontan operation may not be necessary for thromboembolism prophylaxis in paediatric patients, based on large-scale real-world data, with a mean postoperative follow-up duration of 2.1 years. There is room for further studies to reconsider routine warfarin use in patients post-Fontan operation.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Maki W, Aso S, Inuzuka R, et al. Association between warfarin use and thromboembolic events in patients post-Fontan operation: propensity-score overlap weighting analyses. Eur J Cardiothorac Surg. 2024. PMID: 39563462. doi:10.1093/ejcts/ezae413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。